Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (123)	11/4/2000 7:47:15 AM
From: PSC	Read Replies (1) \| Respond to of 447

Dear Richard: I'm wondering what your opinion is of the concept that there is room for more than one drug product for a given target in the oncology market. If this is the case, then there's definitely room for OSI-774. E.g.: Taxol/taxotere; tamoxifen/new aromatase inhibitors; etc. Assuming that giving a drug once a week (OSI) is more attractive than having to take it daily (Iressa) all other things being equal, there may be some value to OSI over Iressa (AZ's drug). OSI is really only 1 year behind Iressa...and actively looking for and courting big Pharma partners, so some of us think the race is indeed on.